Merck Acquires OncoImmune

AbbVie to Acquire ImmunoGen for $10.1 Billion

November 30, 2023

Biotechnology

AbbVie has entered into a definitive agreement to acquire ImmunoGen for $31.26 per share in cash, valuing the company at approximately $10.1 billion. The deal gives AbbVie commercial rights to ELAHERE (mirvetuximab soravtansine-gynx) and ImmunoGen's ADC pipeline, expanding AbbVie's oncology capabilities; the transaction is expected to close in mid-2024 subject to shareholder and regulatory approvals.

Gilead Sciences Acquires Immunomedics

September 13, 2020

Biotechnology

Gilead Sciences agreed to acquire Immunomedics for $88.00 per share in an all-cash transaction valuing Immunomedics at approximately $21 billion. The acquisition gives Gilead global rights (outside certain Asian territories) to Trodelvy, an FDA‑approved antibody‑drug conjugate for metastatic triple‑negative breast cancer, and accelerates Gilead’s expansion into oncology.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

Chimerix Acquires Oncoceutics

January 7, 2021

Biotechnology

Chimerix (NASDAQ: CMRX) acquired clinical-stage Oncoceutics, gaining the late-stage oncology candidate ONC201 to expand its oncology pipeline. The deal closed January 7, 2021, for $78 million (half stock, half cash) plus potential milestones and royalties.

Merck Acquires Pandion Therapeutics

February 25, 2021

Biotechnology

Merck will acquire Pandion Therapeutics for $60 per share in cash, representing an approximate total equity value of $1.85 billion, via a tender offer and subsequent merger. Pandion is a clinical-stage biotechnology company focused on precision immune modulators (TALON platform) with lead candidate PT101 targeting regulatory T cells for autoimmune diseases; the transaction is expected to close in the first half of 2021 subject to customary conditions.

Merck to Acquire Imago BioSciences, Inc.

November 21, 2022

Pharmaceuticals

Merck has agreed to acquire clinical-stage biopharmaceutical company Imago BioSciences for $36.00 per share, representing an approximate equity value of $1.35 billion. The acquisition adds Imago's lead LSD1 inhibitor bomedemstat to Merck's hematology pipeline and is expected to close after a tender offer and customary regulatory clearances in early 2023.